Genetic Resilience—Can We Find Treatments for the Sick by Studying the Healthy?
Thirteen “escapees” of childhood illness offer hope of finding protective variants that may pay dividends.
ALL NEWS
6397 RESULTS
Sort By:
- Most Recent
- Most Commented
NOVA Documentary Personalizes Alzheimer’s Research and Clinical Trials
A NOVA special gets up close and personal with Alzheimer’s researchers and their patients, asking if this disease can be stopped.
Antioxidant Response Might Explain Protective Tau Allele
Scientists report that the transcription factor NRF2 regulates tau expression, stimulating production of a protective isoform.
Rademakers and Traynor Share Potamkin Prize
Neurogeneticists honored for their discoveries, especially of repeat expansions that cause ALS/FTD.
AD-Related Dementias Summit 2016: Progress, Aims, Dollars
NAPA's latest collective exercise was a conference to update the field on progress in the past three years and advise the NIH on how to spend the next round of funds.
Alzheimer's Disease-Related Dementias 2016 Summit
AD-Related Dementias Summit 2016: Progress, Aims, Dollars At 2016 Summit, Field Tackles AD-Related Dementias One By One Did you know the U.S. National Alzheimer’s Project Act covers Lewy body, frontotemporal, vascular, and mixed dementias, as well? It doe
At 2016 Summit, Field Tackles AD-Related Dementias One By One
A bit less strapped for funding, researchers are considering the next steps for Lewy body, frontotemporal, and vascular dementia.
Drug Trials in Frontotemporal Dementia: Can Field Push Forward Together?
At a workshop of the Frontotemporal Dementia Treatment Study Group, advocates and regulatory scientists urged leaders from industry and academia to forge a collaborative approach while the field is still young.
WANTED: Biomarkers for Drug Trials in Frontotemporal Dementia
Hoping for better luck in clinical trials than their Alzheimer’s colleagues had in the past decade, FTD researchers are now chasing biomarkers. It’s slim pickings so far, but neurofilament, tau PET, and MRI are showing promise.
Frontotemporal Dementia Study Group Workshop: Building an Infrastructure to Support FTLD Therapeutic Development
Drug Trials in Frontotemporal Dementia: Can Field Push Forward Together? WANTED: Biomarkers for Drug Trials in Frontotemporal Dementia Regulators Tell Frontotemporal Dementia Community: We Play on Your Team Earlier this month in Washington, D.C., 95 scien
Regulators Tell Frontotemporal Dementia Community: We Play on Your Team
Citing “fantastic opportunity,” FDA and EMA call for rigorous science. Agency scientists tell FTD Treatment Study Group: Explore individualized outcomes, and connect biomarkers to meaningful improvement.
Paper Alert: Could Antisense Therapy One Day Squelch Toxic Repeats in ALS or FTD?
C9ORF72 repeats create RNA foci and dipeptide aggregates in mice, but antisense oligonucleotides suppress them.
Reining in APP’s Early Moves Could Curb Aβ
Backtracking of newly synthesized amyloid precursor protein from the Golgi to the ER facilitates APP modification and Aβ production.
New C9ORF72 Mice Develop Symptoms Resembling ALS/FTD
Compared with previously published model lines, these animals develop more features of amyotrophic lateral sclerosis and frontotemporal dementia.
New Dementia Research Institute Announced for the U.K.
Search begins for director of £250 million venture.
Current Filters
- Date Range : All x